By mid-July, COVID-19 had surpassed 12 million cases shown, more than 500,000 deaths and was still gaining ground worldwide. The virus is basically transmitted through respiratory droplets that use ACE2, a protein on the surface of many types of mobile phones, as an access point. Basically, this protein acts as a gateway for the virus to enter your body.
Researchers in the field rushed to locate a vaccine as soon as possible, as well as explore other medical options, such as leveraging existing medications and looking for other preventive measures, and asked what role hashish can play.
Now that only a third of states have not legalized some form of hashish, a question is asked in clinical communities as well as in some households: can hashish combat COVID-19?
Previous studies have shown that several cannabinoids, which are herbal compounds of the plant, have shown anti-inflammatory and antiviral properties. One of the non-unusual highs is CBD. These cannabinoids can potentially evolve to treat or decrease lung inflammation due to coronavirus. Unlike tocilizumab, a prescription drug, CBD does not cause side effects such as inflammation of the pancreas or the accumulation of triglycerides, behavior or emotions.
Another positive aspect of CBD is that it was already approved in 2018 through the FDA for the remedy of seizures in young people over 2 years of age as a safe option against other drugs.
Current studies use other combinations of CBD to help expand preventive methods opposed to the virus. Examples may also come with a CBD-based mouthwash or throat gargles that would possibly minimize viral access to the coronavirus.
Another advantage of the CBD-based remedy may be simply decreasing anxiety caused by tension or concern about the virus. And hash terpenes, which are herbal compounds found in the flower/button of the hash plant, can act as antiviral agents.
A recent review from the University of Lethbridge in Alberta, Canada, which has since been sent to a peer-reviewed clinical journal, noted that hashish may decrease the virus’s access point and can also block proteins that allow access to the body.
However, one challenge is that some members of the U.S. clinical network. They are skeptical about hash research, as some studies have been funded through the industry and there are also complex federal regulations related to plant use, even if states adopt it.
Pathway Rx, Inc. and Swysh Inc. worked in partnership with the University of Lethbridge in their study, and other Canadian hash corporations such as Curaleaf and Canopy Growth have also partnered with universities to conduct hash studies. Keep in mind that the industry in general has been associated and funded by university studies for many years, only in fitness care, but in technology, engineering and many other sectors.
What does all this mean? This means that rumors of initial studies on hashish that promise to be effective against coronavirus have merit, but there is still no false evidence for a complete conclusion.
To get to this point, more studies and exploration is needed on how hashish can treat or save COVID-19, adding greater team spirit between universities and industry in the United States. Concern about breaking federal law or a possible loss of investment. Array can simply drive those efforts.